Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment

Key Takeaways

• Silexion Therapeutics submitted Phase 2/3 clinical trial application to Germany’s BfArM for SIL204 in KRAS-driven locally advanced pancreatic cancer
• SIL204 is a small interfering RNA (siRNA) therapy targeting KRAS mutations, representing a novel approach to treating aggressive pancreatic tumors
• The submission advances Silexion’s lead RNA interference therapy toward potential regulatory approval in European markets

---

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced April 28, 2026, the successful submission of a Clinical Trial Application (CTA) to Germany’s Federal Institute for Drugs and Medical Devices (BfArM) for its Phase 2/3 study of SIL204 in patients with KRAS-driven locally advanced pancreatic cancer.

Revolutionary RNA Interference Approach

SIL204 represents a breakthrough in pancreatic cancer treatment, utilizing small interfering RNA (siRNA) technology to directly target KRAS mutations. KRAS mutations occur in approximately 90% of pancreatic adenocarcinomas, making them historically “undruggable” targets until recent advances in RNA interference therapies.

The clinical-stage biotechnology company is pioneering RNAi therapies specifically designed for KRAS-driven cancers, addressing one of oncology’s most challenging therapeutic targets. Pancreatic cancer remains one of the deadliest malignancies, with five-year survival rates below 10%.

Market Impact and Regulatory Pathway

The German submission marks a critical milestone for Silexion’s European regulatory strategy. Germany’s BfArM approval could facilitate broader European Medicines Agency (EMA) acceptance and accelerate patient access across EU markets.

Phase 2/3 trials combine efficacy evaluation with pivotal registration-enabling data collection, potentially streamlining the path to market approval. This dual-phase approach reflects confidence in SIL204’s safety profile established in earlier studies.

Competitive Landscape

Silexion’s RNA interference approach differentiates from traditional small molecule KRAS inhibitors by directly silencing KRAS gene expression rather than blocking protein function. This mechanism could overcome resistance patterns observed with current KRAS G12C inhibitors like sotorasib and adagrasib.

The locally advanced pancreatic cancer indication represents a significant unmet medical need, as these patients typically have limited surgical options and poor responses to conventional chemotherapy regimens.

---

Frequently Asked Questions

What makes SIL204 different from existing pancreatic cancer treatments?

SIL204 uses RNA interference technology to directly silence KRAS gene expression, targeting the root cause of 90% of pancreatic cancers rather than just blocking downstream effects like traditional chemotherapy.

When could SIL204 become available to patients?

Following Phase 2/3 trial completion and regulatory review, SIL204 could potentially reach European markets by 2028-2029, pending positive trial results and regulatory approval.

How significant is KRAS targeting for pancreatic cancer treatment?

KRAS mutations drive approximately 90% of pancreatic cancers and were considered “undruggable” until recently. Successfully targeting KRAS could transform outcomes for the vast majority of pancreatic cancer patients.